Home Astellas

Astellas

acquired
Post-IPO Round
Pharmaceutical R&D Manufacturer
Basic
Enterprise Profile
LinkedIn

Basic Information

Astellas Pharma is a Japanese pharmaceutical research and development company, primarily engaged in the pharmaceuticals and related products business, operating in more than 70 countries worldwide. The company has approximately 16,000 employees, with core products including the anticancer drugs XTANDI, XOSPATA, and PADCEV; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB); and Prograf, an immunosuppressant used in organ transplantation.
Astellas Pharma, Inc.
Tokyo,Tokyo,Japan
more than 500 people
January 01, 2005
--

Enterprise Profile

Industrial Sector
New Drug Development Immune Cell Therapy Biological Drug Production
Technology
Gene Technology Targeted Technology Immunological Techniques Cell Technology Stem Cell Technology Protein Technology
Concept
Disease Treatment Tumor Prostate Cancer Leukemia
Application Scenarios
Innovative Drugs Prescription Drug Monoclonal Antibody Bispecific Antibody ADC (Antibody-Drug Conjugate) Cell and Gene Therapy AI+Pharmaceuticals